VYNE Q3 2022 Earnings Report
Key Takeaways
VYNE Therapeutics reported its third-quarter results, highlighting the progress of its InhiBETTM BET inhibitor platform with the anticipated enrollment of the first patient in the Phase 1a/b trial for VYN201. The company also made progress in the VYN202 program and continued to analyze the Phase 2a data for FMX114.
Received IND clearance for pan-BD BET inhibitor, VYN201 and anticipate enrolling the first patient in Phase 1a/b trial for Vitiligo this month.
Continued progression of discovery and development of oral, BD2 selective VYN202 program.
Expanded analysis of FMX114 Phase 2a trial results suggests FMX114 may have the potential to effectively treat patients with moderate-to-severe atopic dermatitis; VYNE currently evaluating development strategy for FMX114.
VYNE anticipates that its cash and cash equivalents and restricted cash as of September 30, 2022 will be sufficient to fund its operations into the fourth quarter of 2023.
VYNE
VYNE
Forward Guidance
VYNE anticipates that its cash and cash equivalents and restricted cash as of September 30, 2022 will be sufficient to fund its operations into the fourth quarter of 2023.